Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3216-3221

  Ripamonti, Carla ^a   Groff, Liliana ^a   Brunelli, Cinzia ^a   Polastri, Daniela ^a   Stavrakis, Alessandro ^a   De Conno, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031726504     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3216     Document Type: Article

References (43)

1. World Health Organization: Cancer Pain Relief (ed 2) Geneva, Switzerland, World Health Organization, 1996
2. Cherny NJ, Chang V, Frager G, et al: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76:1283-1293, 1995
3. Bruera E, MacMillan K, Hanson J: Palliative care in a cancer center: Results in 1984 versus 1987. J Pain Symptom Manage 5:1-5, 1990
4. Coyle N, Adelhart J, Foley KM, et al: Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 5:83-93, 1990
5. Kalso E, Heiskanen T, Rantio M, et al: Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study. Pain 67:443-449, 1996
6. Morley JS, Watt JWG, Wells JC, et al: Methadone in pain uncontrolled by morphine. Lancet 342:1243-1244, 1993
7. Galer BS, Coyle N, Pasternak GW, et al: Individual variability in the response to different opioids: Report of five cases. Pain 49:87-91, 1992
8. Ripamonti C, Bruera E: CNS adverse effects of opioids in cancer patients: Guidelines for drug treatment. CNS Drugs 8:21-37, 1997
9. Gourlay GK, Cherry DA, Cousin MJ: A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297-312, 1986
10. Ripamonti C, Zecca E, Brunelli C, et al: Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 6:841-843, 1995
11. Ventafridda V, Ripamonti C, Bianchi M, et al: A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1:203-207, 1986
12. Bruera E, Watanabe S, Fainsinger RL, et al: Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 62:141-146, 1995
13. De Conno F, Groff L, Brunelli C, et al: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14:2836-2842, 1996
14. Ripamonti C, Zecca E, Bruera E: An update on the clinical use of methadone for cancer pain. Pain 70:109-115, 1997
15. Crews JC, Sweeney NJ, Denson DD: Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer 72:2266-2272, 1993
16. Manfredi PL, Borsook D, Chandler SW, et al: Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain 70:99-101, 1997
17. Health and Welfare Canada: Cancer Pain: A Monograph on the Management of Cancer Pain. Ottawa, Canada, Health & Welfare Canada, Minister of Supply and Services, H42-2/5, 1984E
18. Levy MH: Pharmacological treatment of cancer pain. N Engl J Med 335:1124-1132, 1996
19. Agency for Health Care Policy Research: Management of Cancer Pain. Clinical Practice Guidelines. Rockville, MD, US Department of Health and Human Services. AHCPR Publications no. 94-0592, March 1994, p 52
20. Houde RE: Misinformation: Side effects and drug interactions, in Hill CS, Fields WS (eds): Advances in Pain Research and Therapy. New York, NY, Raven, 1989, pp 145-161
21. Portenoy RK, Coyle N: Controversies in the long-term management of analgesic therapy in patients with advanced cancer. J Pain Symptom Manage 5:307-319, 1990
22. Morley JS, Makin MK: Letter to the Editor. Pain 70:109-115, 1997
23. Lawlor PG, Turner K, Hanson J, et al: Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer 82:1167-1173, 1998
24. Bruera E, Pereira J, Watanabe S, et al: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852-857, 1996
25. Hanks GW, De Conno F, Ripamonti C, et al: Morphine in cancer pain: Modes of administration. BMJ 312:823-826, 1996
26. Kalso E, Vainio A: Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639-646, 1990
27. Ventafridda V, De Conno F, Ripamonti C, et al: Quality-of-life assessment during a palliative care program. Ann Oncol 1:415-420, 1990
28. Tamburini M, Rosso S, Gamba A, et al: A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 3:565-570, 1992
29. Cuzick J: A Wilcoxon-type test for trend. Stat Med 4:87-90, 1985
30. Lawlor PG, Turner K, Hanson J, et al: Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain 72:79-85, 1997
31. Ripamonti C, De Conno F, Groff L, et al: Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. Ann Oncol 9:79-83, 1998
32. Ebert B, Andersen S, Krogsgaard-Larsen P: Ketobemidone, methadone and pethidine are noncompetitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 187:165-168, 1995
33. Gorman AL, Elliott KJ, Inturrisi CE: The d- and 1-isomers of methadone bind to the noncompetitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223:5-8, 1997
34. Elliot K, Kest B, Man A, et al: N-methyl-d-aspartate (NMDA) receptors, mu and kappa opioid tolerance and perspectives on new analgesic drug development. Neuropsychopharmacology 13:347-356, 1995
35. Trujillo K: Effects of noncompetitive N-methyl-d-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 13:301-307, 1995
36. Yamamoto T, Yaksh TL: Studies on the spinal interaction of morphine and the NMDA antagonist Mk-801 on the hyperaesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 135:67-70, 1992
37. Tiseo PJ, Inturrisi CE: Attenuation and reversal of morphine tolerance by competitive N-methyl-D-aspartate receptor antagonist LY 274614. J Pharmacol Exp Ther 264:1090-1096, 1993
38. Elliott K, Minami N, Kohesnidov Y, et al: The NMDA receptor antagonist LY 274614 and Mk-801 and the nitric oxide synthase inhibitor NG-nitro-L-arginine attenuate analgesic tolerance to the mu-opioid morphine. Pain 56:69-75, 1994
39. Clark JK, Kalen GE: Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage 10:310-314; 1995
40. Smith MJ, Watt JA, Cramond T: Morphine-3-glucuronide: A potent antagonist of morphine analgesia. Life Sci 47:579-585, 1990
41. Morley J, Miles JB, Wells JC, et al: Paradoxical pain. Lancet 340:1045, 1992
42. Nilsson MI, Meresaar U, Anggard E, et al: Clinical pharmacokinetics of methadone. Acta Anaesth Scand 74:66-69, 1982
43. Jaffe JH, Martin WR: Opioid analgesics and antagonists, in Goodman Gilman A, Goodman LS (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY, Pergamon, 1990, p 508